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Abstract
Purpose—Sequence dependent improved efficacy of topoisomerase I followed by topoisomerase 
2 inhibitors was assessed in a randomized phase II study in extensive-stage small cell lung cancer 
(SCLC).
Methods—Patients with previously untreated extensive stage SCLC with measurable disease, 
ECOG performance status of 0 to 3 and stable brain metastases were eligible. Arm A consisted of 
topotecan (0.75 mg/m2) on days 1, 2 and 3, etoposide (70 mg/m2) and cisplatin (20 mg/m2) [PET] 
on days 8, 9 and 10 in a 3-week cycle. Arm B consisted of irinotecan (50 mg/m2) and cisplatin (20 
mg/m2) on days 1 and 8 followed by etoposide (85 mg/m2 PO bid) on days 3 and 10 [PIE] in a 3-
week cycle.
Results—We enrolled 140 patients and randomized 66 eligible patients to each arm. Only 54.5% 
of all patients completed the planned maximum 6 cycles. There were grade ≥3 treatment-related 
adverse events in approximately 70% of the patients on both arms including 6 treatment-related 
grade 5 events. The overall response rates (CR+PR) were 69.7% (90% CI: 59.1–78.9%, 95% CI: 
57.1–80.4%) for arm A and 57.6% (90% CI: 46.7–67.9%, 95% CI:44.8–69.7%) for arm B. The 
median PFS and OS were 6.4 months (95% CI: 5.4–7.5 months) and 11.9 months (95% CI: 9.6–
13.7 months) for arm A and 6.0 months (95% CI: 5.4–7.0 months) and 11.0 months (95% CI: 8.6–
13.1 months) for arm B.
Conclusion—Sequential administration of topoisomerase inhibitors did not improve on the 
historical efficacy of standard platinum-doublet chemotherapy for extensive stage SCLC.
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Introduction
Small cell lung cancer (SCLC) constitutes approximately 10–15% of all cases of lung cancer 
diagnosed in the US.[1,2] A large majority, more than two-thirds, of the SCLC patients 
present with extensive stage disease, indicating disease spread beyond the primary 
hemithorax and contiguous regional lymph nodes.[3,4] The initial chemotherapy 
responsiveness in SCLC and improved survival fueled the early optimism that SCLC is 
potentially curable with systemic therapy.[5] The two drug regimen, cisplatin plus 
etoposide, became the most commonly employed systemic therapy due to its improved 
toxicity profile and efficacy in comparison to the older CAV or CAE regimens.[6,7]
Despite the high response rate associated with frontline regimens, extensive stage SCLC 
essentially remains an incurable disease. Patients with resistant disease suffer early relapse 
with disease progression occurring within a year of treatment. Those with initially 
chemosensitive disease achieve longer time to disease progression but show diminished 
tumor responsiveness to chemotherapy at the time of recurrence. Despite the use of second 
line therapy or retreatment with the frontline regimen in cases with durable response off 
chemotherapy lasting more than 90 days, the overall survival at 5 years remains less than 
5%.[8–10] New approaches explored in the last two decades have yielded no major 
therapeutic breakthroughs in this disease. While topoisomerase 2 (TOP-2) active agents such 
as etoposide and doxorubicin have long showed activity, the topoisomerase-1 (TOP-1) 
camptothecin derivatives inhibitors: topotecan and irinotecan, also later showed activity 
initially in the salvage setting and subsequently as part of frontline therapy.[11–14] The 
empiric addition of topotecan to frontline therapy in extensive stage SCLC failed to improve 
on the efficacy of cisplatin/etoposide, but substitution of irinotecan for etoposide in 
combination with cisplatin produced superior outcome in Japanese patients.[15,16] 
However, large randomized studies in the Western population failed to reproduce this 
efficacy benefit of irinotecan, and demonstrated greater toxicity.[17,18]
Rubin et al. explored the mechanism of action and development of resistance to the TOP-1 
agents, camptothecins in preclinical models. These studies provided strong rationale for the 
further integration of these agents into the frontline therapy of extensive stage SCLC. This 
preclinical work showed that resistance to TOP-1 inhibitors may be mediated in part, by the 
down-regulation of the TOP-1 target, along with a compensatory increase in TOP-2 
expression. Conversely, treatment with TOP-2 inhibitors results in a down-regulation of 
TOP-2 and compensatory up-regulation of TOP-1.[19,20] Furthermore, point mutations in 
TOP-1 resulted in increased sensitivity to cisplatin,[21] thus suggesting that intercalating 
cisplatin within the TOP-1, TOP-2 alternations might further enhance drug activity and 
overcome resistance. Initial validation of this preclinical observations was carried out in 
several phase I studies.[22–25] Consistent with the preclinical model prediction, peripheral 
blood monocytes showed reciprocal changes in the expression of TOP-1 and TOP-2 
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enzymes with sequential administration of their inhibitors. Since both TOP-1 and TOP-2 
inhibitors are effective SCLC therapy, we expected a systematic exploitation of this 
mechanism to induce greater susceptibility of SCLC to the cytotoxicity of these agents and 
result in improved response and survival. The Eastern Cooperative Oncology Group 
therefore conducted this randomized phase II study to evaluate the triple regimens of 
topotecan followed by etoposide plus cisplatin (PET) as well as the combination of 
irinotecan plus cisplatin followed by oral etoposide (PIE) in patients with previously 
untreated extensive stage SCLC.
Materials and Methods
Eligibility
Eligibility included extensive stage SCLC with measurable disease and an ECOG 
performance status of 0–3. Prior systemic chemotherapy or thoracic irradiation was not 
allowed but prior radiotherapy for CNS metastasis was permitted, provided the patient had 
no evidence of progression in the brain before enrolment. Other salient eligibility 
requirements included: adequate hematologic, hepatic, and renal function within 4 weeks 
before randomization defined as WBC > 4000/mm3 and platelets > 100,000/mm3, bilirubin 
< 2×upper limit of normal, SGPT (ALT) and SGOT (AST) < 2.5×upper limit of normal or < 
5 times upper limit of normal in patients with liver metastases; calculated creatinine 
clearance > 30mls/minute. Patients with prior diagnosis of any other type of malignancies 
within 5 years of enrolment were excluded except for treated basal or squamous cell skin 
cancer, or carcinoma in situ of the cervix.
Treatment
Eligible patients were randomized to one of two arms (A or B). Patients on arm A received 
topotecan (0.75 mg/m2 IV) on days 1, 2 and 3 followed one week later by etoposide (70 
mg/m2 IV) and cisplatin (20 mg/m2 IV) on days 8, 9 and 10 in a 3-week cycle schedule 
(PET). G-CSF: 5mcg/kg/day subcutaneously was administered starting day 11 of each cycle 
until WBC recovery > 10,000/mm3. Treatment on arm B consisted of irinotecan (50 mg/m2 
IV) and cisplatin (20 mg/m2 IV) on days 1 and 8 and etoposide (85 mg/m2 PO bid) on days 
3 and 10 of each cycle (PIE). Cycles were repeated every 3 weeks for a total of 6 cycles in 
the absence of disease progression, withdrawal of consent or intolerable toxicities that, in the 
opinion of the treating physician, threatened the well-being of the patient.
Dose Modification
Before starting a new cycle, patients were evaluated for treatment emergent toxicities graded 
according to the National Cancer Institute Common Toxicity Criteria for Adverse Events 
(NCI-CTCAE) version 2. In addition to instituting appropriate supportive care measures, 
dose modification was effected as appropriate for the agent presumed most likely 
responsible for the toxicity. Accordingly, topotecan dose was reduced by 25% for febrile 
neutropenia, or a nadir absolute neutrophil count of <500/mm3 for 5 days or more during the 
previous cycle, and by 50% for nadir platelets count <25,000/mm3.
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Irinotecan dose was reduced by 25% for febrile neutropenia, a nadir absolute neutrophil 
count of < 500/mm3 lasting ≥5 days or nadir platelets <25,000/mm3 during the previous 
cycle. Etoposide dose was reduced by 25% for febrile neutropenia or nadir ANC of 750–
999/mm3. A 50% dose reduction was instituted for ANC <750/mm3 and platelets 
<50,000/mm3 while a 25–50% dose reduction was required for hepatic toxicity. Renal 
toxicity with creatinine elevation above 2mg/dL, grade 2 neurotoxicity or grade 3 
gastrointestinal toxicity required a 50% reduction in the dose of cisplatin.
Dose re-escalation was allowed in cases of hematologic toxicities as tolerated but not in 
cases of grade 3 or 4 non-hematologic toxicities.
Efficacy
All enrolled patients had documented measurable disease on cross sectional anatomic 
imaging at baseline (not more than two weeks before randomization). Follow-up scans were 
obtained after every 2 cycles during treatment. Post treatment follow up scans were obtained 
once every 3 months for 2 years from study entry and once every 6 months between 2 and 3 
years from study entry. Efficacy was assessed and graded according to the RECIST 1.0 
guidelines as Complete Response (CR), Partial Response (PR), Stable Disease (SD) or 
Progressive Disease (PD). Confirmation of objective response classification (CR or PR) was 
required on a follow up scan obtained not earlier than four weeks from when the patient first 
met the objective response criteria.
Survival
All patients, including those whose protocol therapy was discontinued, were followed for 
response until progression and for survival for 3 years from the date of randomization. There 
were no specific follow-up requirements for patients surviving more than 3 years from study 
entry.
Statistics
Patients were randomized to the two treatment arms in equal numbers using permuted 
blocks without stratification with dynamic balancing on main institutions. The primary study 
endpoint was objective response frequency. The secondary efficacy endpoint was response 
duration. The study design called for a total accrual of 70 patients in each arm in order to 
have 63 eligible patients in the primary analysis. A treatment would be considered 
efficacious if the true response rate exceeded 35%. Using a two-stage design, a treatment 
arm was to be terminated if fewer than 6 objective responses were observed in the first 27 
eligible patients enrolled in that arm. The treatment arm was to be declared efficacious if a 
total of 16 or more objective responses were observed.
For each arm, if the true response frequency was 0.2, the probability of stopping early was 
0.54, and the probability of declaring the treatment efficacious was 0.1. If the true response 
frequency was 0.35, the probability of stopping early was 0.05, and the probability of 
declaring the treatment efficacious was 0.9. This design had 0.44, 0.72 and 0.93 probabilities 
to declare at least one treatment arm efficacious when the true response rates were 0.20 and 
0.25, 0.20 and 0.30, and 0.20 and 0.35 in the two arms, respectively. The corresponding 
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conditional probabilities of selecting the correct treatment arm were 0.82, 0.93 and 0.98. 
These probabilities were determined by simulations. After a total of 9 months of treatment 
plus follow-up on 63 patients, the null hypothesis of a 9-month median survival was to be 
rejected in favor of the alternative that median survival exceeds 9 months if 38 patients were 
still alive. This test had a 0.04 significance level (exact binomial) and an 80% power to 
detect survival distributions where the 33rd percentile was 9 months or longer.
The data cut-off date for this analysis was January 24, 2012. The primary efficacy analyses 
excluded ineligible patients, while the toxicity analysis included all treated patients. Overall 
survival (OS) is defined as the time from randomization to death from any cause, with 
follow-up censored at the date of last contact. Progression free survival (PFS) was defined as 
time from randomization to documented progression or death without progression. Patients 
without documented progression or death reported were censored at the time of last 
documented disease evaluation. Duration of response was defined as the length of time 
between the date of confirmed response and the date of disease progression. Patients without 
documented progression were censored at the time of last documented disease evaluation.
Kaplan-Meier estimates were used for event-time distributions. Fisher's exact test 
(categorical variable with two categories), χ2 test (categorical variable with three or more 
categories) and Wilcoxon test (continuous variable) were used to test for differences in 
baseline characteristics between the two arms. Confidence intervals for response frequencies 
were computed using the method of Atkinson and Brown.[26]
Results
The study was conducted between March 2004 and April 2008, and accrued a total of 140 
patients. There were 6 ineligible patients and 2 patients who never started treatment, leaving 
132 cases in the primary analysis (Figure 1 is a consort diagram summarizing the patient 
enrollment and randomization procedures).
Patient Characteristics
Full patient demographic factors and disease characteristics at the time of enrollment are 
presented in Table 1. The two study arms were well matched except for significant 
difference in age at enrollment (median age higher in arm B than arm A; Wilcoxon test p = 
0.039) and better kidney function in patients in arm A than in arm B (Wilcoxon test p = 
0.046).
Treatment
54.5% of the enrolled patients received the planned maximum 6 cycles of treatment (59.1% 
in arm A and 50% in arm B). Two eligible patients never started treatment; one due to 
withdrawal of consent, the other because of an elevated liver function test. One of 6 
ineligible patients did not receive treatment.
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Adverse Events
All patients who started assigned treatment, including ineligible patients, were included in 
the analysis of adverse events, giving 69 patients on arm A (PET) and 68 patients on arm B 
(PIE) for the adverse event analysis. More than 70% of the patients on both arms 
experienced treatmentrelated adverse events of grade 3 or higher. There were 6 treatment-
related grade 5 events, all of which were due to infectious complication and neutropenia. 
Eight additional grade 5 events were considered unrelated to treatment. Details of all grades 
3, 4 & 5 adverse events are provided in Table 2.
Response
Primary efficacy analysis was based on the 66 patients enrolled on each arm of the study. 
There were 46 PRs on arm A (PET) and 1 CR and 37 PRs on B (PIE). The overall response 
rates (CR+PR) were 69.7% (90% CI: 59.1–78.9%, 95% CI: 57.1–80.4%) for arm A (PET), 
and 57.6% (90% CI: 46.7–67.9%, 95% CI: 44.8–69.7%) for arm B (PIE), all adjusted for the 
two-stage design. Based on a prespecified response rate of 35%, both arms of the study met 
the required efficacious threshold defined in the study design. Twenty seven cases were 
inevaluable (13 on arm A, 14 on arm B). The median response duration was 6.0 months 
(95% CI: 5.0–7.0 months) for arm A and 6.0 months (95% CI: 5.0–8.3 months) for arm B 
(Figure 2).
Survival
The median OS was comparable between both arms, 11.9 months (95% CI: 9.6–13.7 
months) for arm A and 11.0 months (95% CI: 8.6–13.1 months) for arm B (Figure 3). 
Similarly, median PFS was 6.4 months (95% CI: 5.4–7.5 months) for arm A and 6.0 months 
(95% CI: 5.4–7.0 months) for arm B (Figure 4). There were 43 patients in arm A (PET) and 
39 patients in arm B (PIE) who survived more than 9 months. Under the null hypothesis of a 
9-month median survival, the probabilities of having 39 or more, and 43 or more patients 
alive after 9 months were 0.009 and 0.088 for patients treated with the PET and PIE 
regimens, respectively (exact binomial).
Discussion
The sequence dependent potentiation of TOP-1 and TOP-2 inhibitors provided sufficient 
rationale to test the regimens of etoposide /cisplatin combination alternating with topotecan 
as well as the combination of irinotecan/cisplatin followed by oral etoposide in extensive 
SCLC patients. The study met the prespecified statistical endpoints of response rate of 35% 
but did not confer any significant improvement in progression free or overall survival when 
compared to the historical efficacy data of standard cisplatin /etoposide doublet 
chemotherapy. Despite the preclinical rationale, the strategy of alternating topoisomerase 
inhibitors in order to improve clinical efficacy could not be validated in this study.
Topotecan as a single agent showed promising single agent activity with objective response 
in approximately 40% of previously untreated patients,[27] and comparable efficacy with 
better tolerability than multi-agent chemotherapy, CAV, in the salvage setting.[28] The 
integration of topotecan into the frontline as part of a triplet therapy in the form of 
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maintenance therapy, or in combination with other classes of cytotoxic chemotherapy was 
not promising and led to increased toxicity and diminished quality of life.[15,29–33] 
Similarly a phase III study compared topotecan/cisplatin to topotecan/etoposide or cisplatin/
etoposide in chemotherapy-naïve extensive stage SCLC and showed the topotecan/etoposide 
as inferior. Topotecan/cisplatin was superior to cisplatin/etoposide (median survival: 44.9 
vs. 40.9 weeks; p = 0.40; median TTP: 27.4 vs. 24.3 weeks, p = 0.01) and showed 
significantly higher overall response rates for the (55.5% vs. 45.5%, p = 0.01). However, 
increased hematologic toxicity did not support the standard use of this for SCLC.[34] The 
combination of oral topotecan with IV cisplatin appeared better tolerated, but survival was 
not superior to standard regimen of etoposide/cisplatin.[35] The Hellenic Oncology 
Research Group studied sequential (4 cycles of cisplatin etoposide followed by 4 cycles of 
topotecan) versus alternating (1 cycle of cisplatin/etoposide alternating with 1 cycle of 
topotecan) schedule but showed no significant difference in response rates, median time to 
progression (TTP) or OS.[36]
Irinotecan is an established frontline agent for the treatment of SCLC in Japanese patients, 
with comparable activity but greater toxicity than etoposide –cisplatin in Western 
populations. Irinotecan is likewise frequently used as a salvage regimen in the US patient 
population.[16,8] The result of our study is not superior to the clinical efficacy observed 
with irinotecan as part of a doublet chemotherapy.[37–40] Similarly, the incorporation of 
irinotecan into a triplet regimen of carboplatin, etoposide and irinotecan failed to improve 
the clinical efficacy in a prior study.[41] Given the disparity between the preclinical and 
clinical findings, it seems worthwhile to explore the potential reasons for the failure of these 
two sequential combinations to improve on outcome results. First, one may question 
whether reduced dose intensity of cisplatin to minimize toxicity might have compromised 
the overall efficacy, but a randomized study by Ihde et al showed no dose-dependent effect 
over a 2-fold range of the cisplatin dose intensity.[42] Secondly, while our patient 
population, was mostly Caucasian, SWOG study 0124 showed the outcome with cisplatin/
irinotecan to be similar to cisplatin/etoposide in this population.
Finally, pharmacokinetic and pharmacodynamic correlation in surrogate samples analyzed 
in the course of phase I clinical trials showed that TOP-2 expression induced by TOP-1 
inhibitor therapy is short-lasting (<24 hours) such that for optimal efficacy, the 
administration of a TOP-2 inhibitor should be scheduled to occur within this narrow window 
following the administration of the TOP-1 inhibitor.[43,23] In a study testing sequential 
alternation of TOP-1 and TOP-2 inhibitors in acute leukemia, Saraiya et al showed by 
sequential study of the target leukemia cells that the optimal timing of the sequential 
administration of TOP-1 and TOP-2 inhibitors was approximately 6 hours, and much longer 
interval lacked the reciprocal target modulation and clinical efficacy.[44] In an attempt to 
minimize toxicity, the TOP-2 inhibitor, etoposide, was administered after 72 hours of the 
TOP-1 inhibitor administration in both arms of our study. In conclusion, our results along 
with published reports from other phase II and phase III trials do not support the 
incorporation of topotecan or irinotecan along with standard cisplatin/etoposide regimen in 
the frontline treatment of extensive stage SCLC. The 72 hour based sequential use ofTOP-1 
and TOP-2 inhibitors failed to improve outcomes and produced more toxicity than socalled 
standard etoposide cisplatin. The results from the original phase I study and those from 
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leukemia patients suggest that the 72 hour based sequencing to reduce potential toxicities 
may not have been an adequate test of this hypothesis derived from intriguing preclinical 
observations of a potential mechanism of drug resistance
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Figure 1. 
Consort diagram showing enrolment, eligibility and randomization of patients on the study
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Figure 2. 
Kaplan-Meier curves showing the duration of response in patients who achieved objective 
responses on both arms of the study
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Figure 3. 
Kaplan-Meier curves for overall survival measured from randomization until death or 
censorship for all eligible patients treated on both arms of the study.
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Figure 4. 
Kaplan-Meier curves for progression-free survival measured from time of randomization 
until disease progression, death or censorship for all eligible patients treated on both arms of 
the study
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Table 1
Patient demographics and disease characteristics
Demographic details and comparison of salient patient and tumor characteristics between the 2 arms of the 
study
Variable Category A (PET)
N=66
B (PIE)
N=66
Total
N=132
Age Median (IQR) 60 (53,68) 64 (58,70) 63 (56,69)
Age <65 39(59.1) 33(50.0) 72(54.5)
>=65 27(40.9) 33(50.0) 60(45.5)
Gender Male 41(62.1) 33(50.0) 74(56.1)
Female 25(37.9) 33(50.0) 58(43.9)
Race White 63(95.5) 63(95.5) 126(95.5)
Black 3(4.5) 3(4.5) 6(4.5)
Performance Status 0 27(40.9) 19(28.8) 46(34.8)
1 29(43.9) 35(53.0) 64(48.5)
2 6(9.1) 8(12.1) 14(10.6)
3 4(6.1) 4(6.1) 8(6.1)
Weight Loss in Previous 6 Months <5% 46(69.7) 39(60.9) 85(65.4)
5–<10% 14(21.2) 13(20.3) 27(20.8)
10–<20% 4(6.1) 9(14.1) 13(10.0)
>=20% 2(3.0) 3(4.7) 5(3.8)
Degree of Involvement of Metastatic Sites Single Lesion 3(4.5) 5(7.6) 8(6.1)
Single Site 17(25.8) 16(24.2) 33(25.0)
Multiple Lesions and Sites 46(69.7) 45(68.2) 91(68.9)
Pleural effusion present No 39(59.1) 44(66.7) 83(62.9)
Yes 27(40.9) 22(33.3) 49(37.1)
Pleural effusion malignant No 5(18.5) 0(0.0) 5(10.2)
Yes 5(18.5) 7(31.8) 12(24.5)
Unknown 17(63.0) 15(68.2) 32(65.3)
No 64(97.0) 62(93.9) 126(95.5)
Previous Radiation Yes 5(7.6) 6(9.1) 11(8.3)
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Variable Category A (PET)
N=66
B (PIE)
N=66
Total
N=132
No 65(98.5) 63(95.5) 128(97.0)
Previous Surgery Yes 1(1.5) 3(4.5) 4(3.0)
No 61(92.4) 60(90.9) 121(91.7)
CNS Metastases Yes 5(7.6) 6(9.1) 11(8.3)
Randomization was balanced except for age and kidney function
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